Medplus Health Services Limited (MEDPLUS) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Medplus Health Services Limited ₹708, price ₹654, upside +8.2%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Medplus Health Services Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
57‑month range ₹576.30 – ₹1,290 · fair‑value band ₹495.65 – ₹920.50 · the ₹654.30 price screens below the ₹708.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Medplus Health Services in your weekly email
Every Wednesday you see whether Medplus Health Services is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India.
Show more
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
Stock analysis
Medplus Health Services Limited (MEDPLUS) currently trades at ₹654.30, while our model-based Fair Value estimate is ₹708.08, so the stock looks roughly fairly valued today (gap 7.6%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹652.19 per share, and 7 of the 24 models we run sit above the ₹654.30 price.
Bear case: the Asset-Based group reads lowest at ₹110.21, and 17 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹495.65 (bear) to ₹920.50 (bull), the price of ₹654.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Medplus Health Services Limited reported revenue of ₹68.9B in FY2026 versus ₹37.8B in FY2022, a compound +16.2%/yr. Reported net income was ₹2.2B in FY2026, compounding +23.1%/yr from FY2022.
Key figures
Market cap ₹78.6B (≈ $816M) · P/E ratio 37.3 · P/S ratio 1.19 · EPS (TTM) ₹17.55 · Net margin 3.2% · Return on equity 11.8% · Return on assets (EBIT) 15.7% · Operating margin 2.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 31% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 8%, MEDPLUS screens richer than that median.
Fair Value models
Bear ₹495.65Fair Value ₹708.08Bull ₹920.50
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹8.94 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.6%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+25.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+25.4%
Dividend (yield on the price)0.0%
2026 sits 235% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +9.5% a year for the price and +9.0% for the forecasts.
Compare Medplus Health Services Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 54 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside+8.2% · Below median
Profitability
Return on equity (TTM)11.8% · Top 25%
Return on assets5.6% · Top 25%
Net margin (TTM)2.9% · Above median
Operating margin (TTM)2.9% · Below median
Growth and dividend
Revenue growth21.8% · Top 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Medplus Health Services Limited Fair Value". https://www.fairvalue-calculator.com/stock/MEDPLUS
Frequently asked questions
Is Medplus Health Services Limited (MEDPLUS) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹708.08 versus a price of ₹654.30, about +8% upside (fairly valued).
What is the fair value of MEDPLUS?
Our model-based fair value for Medplus Health Services Limited is ₹708.08 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹654.30.
What is the quality score of MEDPLUS?
Medplus Health Services Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medplus Health Services Limited (MEDPLUS)?
Our model-based price target is the fair value of ₹708.08 (as of Oct 2, 2026) from 24 valuation models. Cautious scenario ₹495.65, optimistic scenario ₹920.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Medplus Health Services Limited stock forecast for 2026?
Our models put fair value at ₹708.08, about +8% upside versus a price of ₹654.30 (fairly valued). Cautious scenario ₹495.65, optimistic scenario ₹920.50. The calculation is refreshed regularly with new filings.
What is the revenue of Medplus Health Services Limited (MEDPLUS)?
Medplus Health Services Limited reported trailing-twelve-month revenue of about ₹72.3B (latest available figure, as of Oct 2, 2026).
What growth is priced into Medplus Health Services Limited (MEDPLUS)?
For today's price to be fair in a discounted-cash-flow model, Medplus Health Services Limited would have to grow free cash flow by +14.0 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.6 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of MEDPLUS use?
Our models discount Medplus Health Services Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.46, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Medplus Health Services Limited that is +14.0 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Medplus Health Services Limited (MEDPLUS) delivered so far?
Over the past 5 years revenue at Medplus Health Services Limited grew +17.6 % a year. The price currently implies +14.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Medplus Health Services Limited (MEDPLUS) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into Medplus Health Services Limited (+14.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Medplus Health Services Limited (MEDPLUS)?
The free-cash-flow yield on the price is 5.14 %: that much free cash flow Medplus Health Services Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Medplus Health Services Limited (MEDPLUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medplus Health Services Limited it is ₹708.08 per share (as of Oct 2, 2026), against a price of ₹654.30. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Medplus Health Services Limited stock overvalued or undervalued in 2026?
As of Oct 2, 2026, MEDPLUS trades below its calculated fair value: price ₹654.30, fair value ₹708.08, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEDPLUS?
No. The price is what the market pays today (₹654.30); the fair value is what the company's own numbers justify (₹708.08). For Medplus Health Services Limited the two are ₹53.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medplus Health Services Limited worth?
The market values Medplus Health Services Limited at about ₹78.6B (market capitalisation, as of Oct 2, 2026). Per share that is ₹654.30; our models calculate a fair value of ₹708.08 per share.
What do the bullish and bearish scenarios say about MEDPLUS?
Our models span a range for Medplus Health Services Limited: cautious scenario ₹495.65, base ₹708.08, optimistic ₹920.50 per share (as of Oct 2, 2026, price ₹654.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of MEDPLUS?
Medplus Health Services Limited trades at a price-to-earnings ratio of 37.3 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹708.08 is built from several models across several years. Other multiples: P/B 4.0, P/S 1.1, EV/EBITDA 18.7.
How solid is the balance sheet of Medplus Health Services Limited (MEDPLUS)?
Balance-sheet figures for Medplus Health Services Limited (as of Oct 2, 2026): return on equity 11.8%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is MEDPLUS from its 52-week high?
Medplus Health Services Limited trades at ₹654.30, about 31% below its 52-week high of ₹953.90 and 1% above the low of ₹649.30 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹708.08 is for.
Which stocks are comparable to Medplus Health Services Limited?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medplus Health Services Limited stock attractive at the current price?
The data as of Oct 2, 2026: price ₹654.30, calculated fair value ₹708.08 (+8%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MEDPLUS calculated?
We run Medplus Health Services Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹708.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medplus Health Services Limited currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medplus Health Services Limited (MEDPLUS)?
The closing price on Oct 1, 2026 was ₹654.30. Our model-based fair value is ₹708.08, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medplus Health Services Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹495.65 to ₹920.50) leaves room in how you read the outcome.
Key figures of Medplus Health Services Limited
How large is the market capitalisation of Medplus Health Services Limited (MEDPLUS)?
The market capitalisation of Medplus Health Services Limited is ₹78.6B (≈ $816M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medplus Health Services Limited (MEDPLUS)?
The price-to-sales ratio of Medplus Health Services Limited is 1.19 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medplus Health Services Limited (MEDPLUS)?
Earnings per share at Medplus Health Services Limited are ₹17.55 (price ÷ EPS = P/E 37.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medplus Health Services Limited (MEDPLUS)?
The net margin of Medplus Health Services Limited is 3.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medplus Health Services Limited (MEDPLUS)?
The return on equity (ROE) of Medplus Health Services Limited is 11.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medplus Health Services Limited (MEDPLUS)?
On an EBIT basis the return on assets of Medplus Health Services Limited is 15.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medplus Health Services Limited (MEDPLUS)?
The operating margin of Medplus Health Services Limited is 2.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medplus Health Services Limited (MEDPLUS)?
Revenue at Medplus Health Services Limited is growing +21.8% versus a year earlier (3y avg +14.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medplus Health Services Limited (MEDPLUS)?
Earnings per share at Medplus Health Services Limited are growing −21.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Medplus Health Services Limited (MEDPLUS) carry?
The net debt of Medplus Health Services Limited is ₹9.6B (fiscal year 2026, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Medplus Health Services Limited in the live analysis
One click puts Medplus Health Services Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
